or Try an Advanced Search...

    Technical Analysis for AKRO - Akero Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 23.16 -1.28% -0.30
    AKRO closed down 1.28 percent on Monday, July 1, 2024, on 82 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical AKRO trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish 0.00%
    MACD Bearish Signal Line Cross Bearish 0.00%
    Shooting Star Candlestick Bearish 0.00%
    Lizard Bearish Bearish Day Trade Setup 0.00%
    20 DMA Support Bullish -1.28%
    Crossed Above 200 DMA Bullish -1.28%
    Hammer Candlestick Bullish -1.28%
    Pocket Pivot Bullish Swing Setup -1.28%
    Volume Surge Other -1.28%
    Doji - Bullish? Reversal -1.28%
    Older End-of-Day Signals for AKRO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 8 hours ago
    200 DMA Resistance about 10 hours ago
    Down 1% about 10 hours ago
    Up 3% about 10 hours ago
    200 DMA Support about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    AKRO Chart by TradingView
    Basic chart:

    Profile

    Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Alcohol Clinical Trial Hepatitis Steatohepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease

    Is AKRO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 11 Wolfe Research starts Akero at outperform, cites MASH drug prospects
    Jun 11 Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
    Jun 8 Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
    Jun 5 Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
    May 29 Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
    May 13 Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
    May 10 Akero Therapeutics GAAP EPS of -$0.90 beats by $0.05
    May 10 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    May 8 Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
    Apr 30 Akero Therapeutics names Scott Gangloff as CTO
    See more AKRO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 53.77
    52 Week Low 11.25
    Average Volume 821,792
    200-Day Moving Average 23.32
    50-Day Moving Average 21.11
    20-Day Moving Average 22.66
    10-Day Moving Average 23.04
    Average True Range 1.31
    RSI (14) 55.36
    ADX 27.54
    +DI 27.98
    -DI 16.83
    Chandelier Exit (Long, 3 ATRs) 21.86
    Chandelier Exit (Short, 3 ATRs) 21.79
    Upper Bollinger Bands 25.60
    Lower Bollinger Band 19.72
    Percent B (%b) 0.58
    BandWidth 25.95
    MACD Line 0.66
    MACD Signal Line 0.67
    MACD Histogram -0.0025
    Fundamentals Value
    Market Cap 1.29 Billion
    Num Shares 55.7 Million
    EPS -2.29
    Price-to-Earnings (P/E) Ratio -10.11
    Price-to-Sales 0.00
    Price-to-Book 1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 24.75
    Resistance 3 (R3) 24.92 24.56 24.49
    Resistance 2 (R2) 24.56 24.16 24.48 24.40
    Resistance 1 (R1) 23.86 23.90 23.68 23.69 24.31
    Pivot Point 23.50 23.50 23.41 23.42 23.50
    Support 1 (S1) 22.80 23.10 22.62 22.63 22.01
    Support 2 (S2) 22.44 22.84 22.36 21.92
    Support 3 (S3) 21.74 22.44 21.84
    Support 4 (S4) 21.57